tbuckley/cabot-search huggingface dataset:
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Authors: Meletios A. Dimopoulos, Xavier Leleu, Philippe Moreau, Paul G. Richardson, Anna Marina Liberati, Simon J. Harrison, H. Miles Prince, Enrique M. Ocio, Sylvie Assadourian, Frank Campana, Laure Malinge, Dorothée Sémiond, Helgi van de Velde, Kwee Yong
Journal: Leukemia (2020)

Abstract The randomized, phase 3 ICARIA-MM study investigated isatuximab (Isa) with pomalidomide and dexamethasone (Pd) versus Pd in patients with relapsed/refractory multiple myeloma and ≥2 prior lines. This prespecified subgroup analysis examined efficacy in patients with renal impairment (RI; estimated glomerular filtration rate &lt;60 mL/min/1.73 m²). Isa 10 mg/kg was given intravenously once weekly in cycle 1, and every 2 weeks in subsequent 28-day cycles. Patients received standard doses of Pd. Median progression-free survival (PFS) for patients with RI was 9.5 months with Isa-Pd ( n = 55) and 3.7 months with Pd ( n = 49; hazard ratio [HR] 0.50; 95% confidence interval [CI], 0.30–0.85). Without RI, median PFS was 12.7 months with Isa-Pd ( n = 87) and 7.9 months with Pd ( n = 96; HR 0.58; 95% CI, 0.38–0.88). The overall response rate (ORR) with and without RI was higher with Isa-Pd (56 and 68%) than Pd (25 and 43%). Complete renal response rates were 71.9% (23/32) with Isa-Pd and 38.1% (8/21) with Pd; these lasted ≥60 days in 31.3% (10/32) and 19.0% (4/21) of patients, respectively. Isa pharmacokinetics were comparable between the subgroups, suggesting no need for dose adjustment in patients with RI. In summary, the addition of Isa to Pd improved PFS, ORR and renal response rates.
A Population-Based Registry of Patients With Inherited Cardiac Conditions and Resuscitated Cardiac Arrest
Authors: Cynthia Rucinski, Annika Winbo, Luciana Marcondes, Nikki Earle, Martin Stiles, Rachael Stiles, Darren Hooks, Kate Neas, Ian Hayes, Jackie Crawford, Andrew Martin, Jonathan R. Skinner
Journal: Journal of the American College of Cardiology (2020)
Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program
Authors: Gregory M. Lucas, Amina Chaudhry, Jeffrey Hsu, Tanita Woodson, Bryan Lau, Yngvild Olsen, Jeanne C. Keruly, David A. Fiellin, Ruth Finkelstein, Patricia Barditch-Crovo, Katie Cook, Richard D. Moore
Journal: Annals of Internal Medicine (2010)

Buprenorphine–naloxone (BUP) is effective for treatment of opioid dependence and may be used in routine medical settings. In this randomized trial of 93 opioid-dependent participants from an HIV cl...
Abstract 16553: Predictors of Hypertensive Response During Exercise Stress Echocardiography
Authors: Siri Kunchakarra, Brendan Martin, Valmiki Maharaj, Yevgeniy Brailovsky, Thriveni Sanagala
Journal: Circulation (2017)

Introduction: Hypertensive response is a safety concern during exercise stress echocardiograms (ESE). Hypertensive response to exercise (HRE) has been shown to be associated with false positive res...
Abstract 18553: Optimal Mean Arterial Pressure in Comatose Survivors of Out-of-hospital Cardiac Arrest: An Analysis of Area Below and Between Blood Pressure Thresholds
Authors: Juan J Russo, Tyler E James, Pietro Di Santo, Bejamin Hibbert, Daniel Ramirez, Trevor Simard, George A Wells, Michel R Le May
Journal: Circulation (2017)

Background: Following an out-of-hospital cardiac arrest (OHCA) cerebral perfusion becomes increasingly dependent on mean arterial pressure (MAP). However, MAP targets to ensure adequate cerebral pe...
Comparison of Early Warning Scoring Systems for Hospitalized Patients With and Without Infection at Risk for In-Hospital Mortality and Transfer to the Intensive Care Unit
Authors: Vincent X. Liu, Yun Lu, Kyle A. Carey, Emily R. Gilbert, Majid Afshar, Mary Akel, Nirav S. Shah, John Dolan, Christopher Winslow, Patricia Kipnis, Dana P. Edelson, Gabriel J. Escobar, Matthew M. Churpek
Journal: JAMA Network Open (2020)

Risk scores used in early warning systems exist for general inpatients and patients with suspected infection outside the intensive care unit (ICU), but their relative performance is incompletely characterized.To compare the performance of tools used to determine points-based risk scores among all hospitalized patients, including those with and without suspected infection, for identifying those at risk for death and/or ICU transfer.In a cohort design, a retrospective analysis of prospectively collected data was conducted in 21 California and 7 Illinois hospitals between 2006 and 2018 among adult inpatients outside the ICU using points-based scores from 5 commonly used tools: National Early Warning Score (NEWS), Modified Early Warning Score (MEWS), Between the Flags (BTF), Quick Sequential Sepsis-Related Organ Failure Assessment (qSOFA), and Systemic Inflammatory Response Syndrome (SIRS). Data analysis was conducted from February 2019 to January 2020.Risk model discrimination was assessed in each state for predicting in-hospital mortality and the combined outcome of ICU transfer or mortality with area under the receiver operating characteristic curves (AUCs). Stratified analyses were also conducted based on suspected infection.The study included 773 477 hospitalized patients in California (mean [SD] age, 65.1 [17.6] years; 416 605 women [53.9%]) and 713 786 hospitalized patients in Illinois (mean [SD] age, 61.3 [19.9] years; 384 830 women [53.9%]). The NEWS exhibited the highest discrimination for mortality (AUC, 0.87; 95% CI, 0.87-0.87 in California vs AUC, 0.86; 95% CI, 0.85-0.86 in Illinois), followed by the MEWS (AUC, 0.83; 95% CI, 0.83-0.84 in California vs AUC, 0.84; 95% CI, 0.84-0.85 in Illinois), qSOFA (AUC, 0.78; 95% CI, 0.78-0.79 in California vs AUC, 0.78; 95% CI, 0.77-0.78 in Illinois), SIRS (AUC, 0.76; 95% CI, 0.76-0.76 in California vs AUC, 0.76; 95% CI, 0.75-0.76 in Illinois), and BTF (AUC, 0.73; 95% CI, 0.73-0.73 in California vs AUC, 0.74; 95% CI, 0.73-0.74 in Illinois). At specific decision thresholds, the NEWS outperformed the SIRS and qSOFA at all 28 hospitals either by reducing the percentage of at-risk patients who need to be screened by 5% to 20% or increasing the percentage of adverse outcomes identified by 3% to 25%.In all hospitalized patients evaluated in this study, including those meeting criteria for suspected infection, the NEWS appeared to display the highest discrimination. Our results suggest that, among commonly used points-based scoring systems, determining the NEWS for inpatient risk stratification could identify patients with and without infection at high risk of mortality.
Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group
Authors: L M Mofenson, J Moye, J Bethel, R Hirschhorn, C Jordan, R Nugent
Journal: JAMA (1992)

To evaluate the efficacy of intravenous immunoglobulin (IVIG) for prevention of viral, opportunistic, and minor bacterial infections in children infected with human immunodeficiency virus (HIV).Randomized, double-blind, placebo-controlled, outpatient clinical trial comparing subjects treated with 400 mg of IVIG per kilogram of body weight every 28 days with those given albumin placebo.Twenty-eight clinical centers in mainland United States and Puerto Rico.Three hundred seventy-six children infected with human immunodeficiency virus with clinical or immunologic evidence of HIV disease, 313 of whom had entry CD4+ counts of at least 0.20 x 10(9)/L (greater than or equal to 200/mm3).The incidence of laboratory-proven and clinically diagnosed viral, opportunistic, and bacterial infections.Viral infections and minor bacterial infections contributed more frequently to morbidity in children with entry CD4+ counts of at least 0.20 x 10(9)/L (together over five times as frequent) than did serious bacterial infection, the primary outcome measure of the trial. Opportunistic infections occurred at a similar rate as laboratory-proven serious bacterial infections. In this group of children, IVIG was significantly associated with a decrease in the rate of viral infections and minor bacterial infections per 100 patient-years (36.0 vs 54.0 episodes of viral infection per 100 patient-years, IVIG vs placebo, P = .01; and 115.1 vs 159.7 episodes of minor bacterial infection per 100 patient-years, IVIG vs placebo, P = .02), as well as a decrease in the rate of serious bacterial infections per 100 patient-years (26.4 vs 48.2 episodes per 100 patient-years; P = .002). There was no apparent difference in the rate of opportunistic infections between treatment arms.Beneficial effect of IVIG was seen across multiple infectious outcome measures, with reductions in serious and minor viral and bacterial infections observed in children with entry CD4+ counts of at least 0.20 x 10(9)/L.
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
Authors: T. Karn, C. Denkert, K.E. Weber, U. Holtrich, C. Hanusch, B.V. Sinn, B.W. Higgs, P. Jank, H.P. Sinn, J. Huober, C. Becker, J.-U. Blohmer, F. Marmé, W.D. Schmitt, S. Wu, M. van Mackelenbergh, V. Müller, C. Schem, E. Stickeler, P.A. Fasching, C. Jackisch, M. Untch, A. Schneeweiss, S. Loibl
Journal: Annals of Oncology (2020)
Lipophilic Statins and Risk of Hepatocellular Carcinoma and Mortality : A Prospective, Nationwide Population with Chronic Viral Hepatitis
Authors: Tracey G. Simon, Ann-Sofi Duberg, Soo Aleman, Hannes Hagström, Raymond T. Chung, Jonas F. Ludvigsson
Journal: Hepatology (2018)

Lipophilic Statins and Risk of Hepatocellular Carcinoma and Mortality : A Prospective, Nationwide Population with Chronic Viral Hepatitis
Amyloid-Rich Pancreatic Neuroendocrine Tumors: a Potential Diagnostic Pitfall in Endoscopic Ultrasound–Guided Fine Needle Aspiration Cytology (EUS-FNAC)
Authors: Alessandro Gambella, Enrico Costantino Falco, Jasna Metovic, Francesca Maletta, Claudio De Angelis, Roberta Maragliano, Silvia Uccella, Donatella Pacchioni, Mauro Papotti
Journal: Endocrine Pathology (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Authors: Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu, Peter V Balint, Heidi Bertheussen, Wolf-Henning Boehncke, Gerd R Burmester, Juan D Canete, Nemanja S Damjanov, Tue Wenzel Kragstrup, Tore K Kvien, Robert B M Landewé, Rik Jozef Urbain Lories, Helena Marzo-Ortega, Denis Poddubnyy, Santiago Andres Rodrigues Manica, Georg Schett, Douglas J Veale, Filip E Van den Bosch, Désirée van der Heijde, Josef S Smolen
Journal: Annals of the Rheumatic Diseases (2020)

To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA).According to the EULAR standardised operating procedures, a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019. Levels of evidence and strengths of recommendations were determined.The updated recommendations comprise 6 overarching principles and 12 recommendations. The overarching principles address the nature of PsA and diversity of both musculoskeletal and non-musculoskeletal manifestations; the need for collaborative management and shared decision-making is highlighted. The recommendations provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs and local glucocorticoid injections are proposed as initial therapy; for patients with arthritis and poor prognostic factors, such as polyarthritis or monoarthritis/oligoarthritis accompanied by factors such as dactylitis or joint damage, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumour necrosis factor (TNF), interleukin (IL)-17A or IL-12/23 should be initiated, taking into account skin involvement if relevant. If axial disease predominates, a TNF inhibitor or IL-17A inhibitor should be started as first-line disease-modifying antirheumatic drug. Use of Janus kinase inhibitors is addressed primarily after bDMARD failure. Phosphodiesterase-4 inhibition is proposed for patients in whom these other drugs are inappropriate, generally in the context of mild disease. Drug switches and tapering in sustained remission are addressed.These recommendations provide stakeholders with an updated consensus on the pharmacological management of PsA, based on a combination of evidence and expert opinion.
Patient Safety News
Authors: Lester M. Crawford, Jr
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neuroinflammatory events after anti-TNFα therapy
Authors: Evripidis Kaltsonoudis, Eleftherios Pelechas, Paraskevi V Voulgari, Alexandros A Drosos
Journal: Annals of the Rheumatic Diseases (2020)

We have read with interest the article by Kopp et al that has been published recently in the Annals of the Rheumatic Diseases. The article deals with the risk of neuroinflammatory events (NIEs) in patients with inflammatory arthritides (IA), receiving tumour necrosis factor alpha (TNFα) inhibitors.1 Their cases were identified from the nationwide registries of Sweden and Denmark, in a prospective observational study. The authors found an increased risk of NIEs after anti-TNFα therapy in patients with spondyloarthropathies (SpAs) as compared with those not receiving TNF blockers, while no consistent and significant risk of NIEs after anti-TNFα treatment in rheumatoid arthritis (RA) patients. They concluded that the risk profile of NIEs in patients receiving TNFα inhibitors differs among patients with different IA which has an impact on decision-making in clinical practice.

In a prospective imaging and electrophysiological study of our clinic, patients with RA and SpAs who were eligible for anti-TNFα therapy had been investigated, during the period May 2009 to December 2011.2 Before …
Abstract 14948: Feasibility of IVUS-Derived FFR as a Novel Technique to Estimate Functional Severity of Coronary Stenosis: Systematic Evaluation of Thresholds to Determine Diseased Segment
Authors: Kuninobu Kashiyama, Shinjo Sonoda, Kensuke Matsushita, Kozo Okada, Kiyoshi Hibi, Kazuo Kimura, Brooke Hollak, Alan C Yeung, Paul G Yock, Peter Fitzgerald, Yasuhiro Honda
Journal: Circulation (2019)

Introduction: IVUS-derived FFR (IVUS-FFR) is a novel technique to estimate functional severity of coronary stenosis. Using a fluid dynamics algorithm, pressure loss (ΔP) across a stenosis is calcul...
Cytomegalovirus Retinitis in Immunosuppressed Hosts
Authors: Peter R. Egbert, Richard B. Pollard, James G. Gallagher, Thomas C. Merigan
Journal: Annals of Internal Medicine (2020)

Abstract Cytomegalovirus (CMV) retinitis presents with typical ophthalmologic appearance in patients with underlying immunosuppressive conditions. Fourteen patients with this disorder were diagnose...
Zabofloxacin 367mg For Five Days Versus Moxifloxacin 400mg For Seven Days In Patients With COPD Exacerbation: A Multicenter, Randomized, Double-Blind, Phase 3, Non-Inferiority Trial
Authors: H. Kim, Y. Lee, Y. M. Oh, C. K. Rhee, S. Kyung, J. Chang, W. Y. Lee, J. S. Kim
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
From the Office of the General Counsel. Corporal punishment in the schools
Authors: D Orentlicher
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peripapillary Retinal Segmentation in OCT Angiography
Authors: Verina Hanna, Glen P. Sharpe, Michael E. West, Donna M. Hutchison, Lesya M. Shuba, Paul E. Rafuse, Marcelo T. Nicolela, Corey A. Smith, Balwantray C. Chauhan
Journal: Ophthalmology (2020)
Commentary: Health Research Needed to Resolve Scientific Issues Surrounding Drinking Water Disinfection
Authors: David Kleffman
Journal: Environmental Health Perspectives (1986)

Disinfection of drinking water will most likely continue in the United States in order to prevent exposure to microbial pathogens that can cause infectious disease. However, the emergence of concerns over possible tox? icological effects, including cancer, mutagenicity, car? diovascular disease, and reproductive effects, may re? quire that we alter or change the disinfection techniques used in this country. Before we change these practices, we must assess the spectrum of possible health effects and determine the level of risk posed by exposure to chemicals in drinking water, including the disinfectants themselves and the disinfection by-products. This will require a continuing research program to develop the scientific data necessary to resolve these issues. In this paper, I will discuss the microbiological, chemical, tox? icological, and epidemiological research that is needed to address these issues.
Landmark perspective: The Australia antigen
Authors: T. J. Gill
Journal: JAMA (1984)

The article by Blumberg and associates describing the antigen that was ultimately found to be associated with infection by the hepatitis B virus (HBV)<sup>1</sup>presents a classic example of serendipity in scientific research and the fact that "chance favors the prepared mind." It also presents a fascinating insight into the nature of the scientific process and the way in which important discoveries are made.<sup>2</sup> The work was careful, logical, and meticulous. It provided solid evidence for the presence of an antigenic system that was later identified as that of the HBV. The initial interpretation of the work was colored by a fortuitous association between the presence of the antigen and patients with leukemia. However, Blumberg and colleagues quickly grasped the true significance of their finding, ie, that the presence of the antigen was associated with blood transfusion and the subsequent development of hepatitis. Their observations became a new
THE SUPPLY OF APPLICANTS: A TIME OF PLENTY
Authors: M R ZAVON
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China
Authors: Cong Ye, Shaozhe Cai, Guifen Shen, Hanxiong Guan, Liling Zhou, Yangyang Hu, Wei Tu, Yu Chen, Yikai Yu, Xuefen Wu, Yuxue Chen, Jixin Zhong, Lingli Dong
Journal: Annals of the Rheumatic Diseases (2020)

The clinical features of rheumatic patients with coronavirus disease 2019 (COVID-19) have not been reported. This study aimed to describe the clinical features of COVID-19 in rheumatic patients and provide information for handling this situation in clinical practice.This is a retrospective case series study. Deidentified data, including gender, age, laboratory and radiological results, symptoms, signs, and medication history, were collected from 2326 patients diagnosed with COVID-19, including 21 cases in combination with rheumatic disease, in Tongji Hospital between 13 January and 15 March 2020.Length of hospital stay and mortality rate were similar between rheumatic and non-rheumatic groups, while the presence of respiratory failure was more common in rheumatic cases (38% vs 10%, p<0.001). Symptoms of fever, fatigue and diarrhoea were seen in 76%, 43% and 23% of patients, respectively. There were four rheumatic patients who experienced a flare of rheumatic disease during hospital stay, with symptoms of muscle aches, back pain, joint pain or rash. While lymphocytopaenia was seen in 57% of rheumatic patients, only one patient (5%) presented with leucopenia in rheumatic cases. Rheumatic patients presented with similar radiological features of ground-glass opacity and consolidation. Patients with pre-existing interstitial lung disease showed massive fibrous stripes and crazy-paving signs at an early stage. Five rheumatic cases used hydroxychloroquine before the diagnosis of COVID-19 and none progressed to critically ill stage.Respiratory failure was more common in rheumatic patients infected with COVID-19. Differential diagnosis between COVID-19 and a flare of rheumatic disease should be considered.ChiCTR2000030795.